NEW YORK, NY, December 15, 2023 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic lateral sclerosis (ALS). The company’s share price rose nearly 30% in trading on Thursday.
Alon Ben-Noon, NeuroSense’s CEO, commented, “As we analyze the PARADIGM trial results, we continue to gain a better understanding of PrimeC’s potential to render a significant and meaningful clinical benefit to people living with ALS. Today we are eager to share these new data with the ALS community, as we believe the PP analysis, demonstrating a statistically significant 37.4% difference in ALSFRS-R in patients treated with PrimeC vs. placebo, is an exceptional result. This data, in conjunction with hopefully correlative neurofilament readouts, will create a regulatory opportunity to advance PrimeC’s development in a breakthrough manner toward the market.”
PrimeC’s meaningful effect magnitude, strong safety profile, and unique mechanism of action will be discussed with the FDA and other regulatory agencies in an End of Phase 2 meeting in H1 2024.
Highlights
NeuroSense’s PARADIGM study is a prospective, multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial. The trial’s primary endpoints include safety and tolerability, and ALS-related biomarkers TDP-43 and Prostaglandin2.
The study demonstrated a statistically significant slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo.
ALSFRS-R is a widely used ALS tracking tool accepted by the FDA, that tracks 12 changes in a person’s physical abilities over time including speech, walking, climbing stairs, dressing/hygiene, handwriting, turning in bed, cutting food, salivation, swallowing, and breathing.
NeuroSense’s lead drug candidate, PrimeC, is a novel extended-release oral formulation composed of a unique fixed-dose combination of ciprofloxacin and celecoxib.
PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.
The trial met its primary endpoint of safety and tolerability with results comparable to placebo, establishing a solid safety profile for PrimeC.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.
Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Country: United States
Website: https://prismmarketview.com
“Exceptional Result”: NeuroSense Therapeutics @NeurosenseT (Nasdaq: $NRSN) Reports New Positive Data from ALS Trialhttps://t.co/d61F4JNKMk#stockstowatch #stocksinfocus #investors #PrismMarketView #PrismMediaWire #PrismDigitalMedia
— PrismMarketView (@PrismMarketView) December 15, 2023
